Scarica l'app Stockscreener
60.06
0.10%
0.06
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CYTK Giù?
Forum
Previsione
Frazionamento azionario
Cytokinetics Inc Borsa (CYTK) Ultime notizie
Cytokinetics Highlights Early MYQORZO Momentum, Eyes Q2 nHCM Phase 3 Catalyst at Barclays Confab - Yahoo Finance
Cytokinetics Teases Q2 ACACIA-HCM Catalyst as MYQORZO Launch Gains Momentum at Leerink Conference - Yahoo Finance
Cytokinetics Teases Q2 Phase 3 ACACIA-HCM Readout as Myqorzo Launch Gains Traction at Citi Conference - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Stockholders to Connect - ACCESS Newswire
Cytokinetics at Barclays Conference: Strategic Growth and Global Ambitions - Investing.com India
Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Leerink Maintains Outperform for Cytokinetics, Incorporated (CYTK) March 2026 - Meyka
Robert Blum Sells 7,931 Shares of Cytokinetics (NASDAQ:CYTK) Stock - MarketBeat
Cytokinetics (NASDAQ:CYTK) EVP Sells $156,779.04 in Stock - MarketBeat
Cytokinetics (CYTK) EVP Callos sells stock to cover RSU taxes - Stock Titan
[Form 4] CYTOKINETICS INC Insider Trading Activity - Stock Titan
Cytokinetics Leaders Gained $16 Million as Insiders, Suit Says - Bloomberg Law News
Cytokinetics at The Citizens Life Sciences Conference: Myqorzo’s Market Potential - Investing.com Canada
Leerink reiterates Cytokinetics stock rating on launch confidence By Investing.com - Investing.com Canada
Cytokinetics Insider Exercises Options Worth Over $920,000 as Heart Drug Hits the Market - Yahoo Finance
Cytokinetics Insider Exercises Options Worth Over $920,000 as Heart Drug Hits the Market - The Motley Fool
Cytokinetics at Leerink Global Healthcare Conference: Strategic Growth in Cardiology - Investing.com Canada
UBS Maintains Neutral on CYTK, Cytokinetics, Incorporated March 2026 - Meyka
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cytokinetics, Incorporated (CYTK) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Leerink Partners Global Biopharma Conference 2026: TEVA, CYTK, IMRX, TNYA And More Set To Present - RTTNews
Rhenman & Partners Asset Management AB Raises Stake in Cytokinetics, Incorporated $CYTK - MarketBeat
Knott David M Jr Purchases Shares of 30,000 Cytokinetics, Incorporated $CYTK - MarketBeat
GW&K Investment Management LLC Takes $9.93 Million Position in Cytokinetics, Incorporated $CYTK - MarketBeat
GABELLI & Co INVESTMENT ADVISERS INC. Makes New $2.06 Million Investment in Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics (CYTK) Analyst Rating: UBS Raises Price Target to $69.00 | CYTK Stock News - GuruFocus
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Ascendis Pharma (ASND) and Avalo Therapeutics (AVTX) - The Globe and Mail
Callos, Cytokinetics EVP, sells $1.6 million in CYTK stock - Investing.com UK
Callos, Cytokinetics EVP, sells $1.6 million in CYTK stock By Investing.com - Investing.com South Africa
Cytokinetics: From Aficamten Trials to MYQORZO Launch—A High-Stakes Race in the HCM Market! - Smartkarma
Cytokinetics (NASDAQ:CYTK) EVP Andrew Callos Sells 26,000 Shares - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Investors to Inquire about Securities Investigation - ACCESS Newswire
Segall Bryant & Hamill LLC Boosts Position in Cytokinetics, Incorporated $CYTK - MarketBeat
Royce & Associates LP Invests $5.50 Million in Cytokinetics, Incorporated $CYTK - MarketBeat
Legato Capital Management LLC Takes Position in Cytokinetics, Incorporated $CYTK - MarketBeat
Fisher Asset Management LLC Raises Stock Holdings in Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics Is Priced For A Big MYQORZO Launch - Finimize
Rafferty Asset Management LLC Has $5.72 Million Holdings in Cytokinetics, Incorporated $CYTK - MarketBeat
CYTK Should I Buy - Intellectia AI
Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Cytokinetics Wins Dual MYQORZO Approvals But Faces Execution And Loss Risks - simplywall.st
Insider Sell: B Parshall Sells 5,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus
EVP at Cytokinetics (NASDAQ: CYTK) sells 886 shares after option exercise - Stock Titan
[144] CYTOKINETICS INC SEC Filing - Stock Titan
Director Lynne Parshall trims Cytokinetics (CYTK) stake in sale - Stock Titan
Cytokinetics to Participate in March Investor Conferences - The Manila Times
Cytokinetics, Incorporated (CYTK) Stock Analysis: A Biotech With A 46.52% Potential Upside - DirectorsTalk Interviews
Cytokinetics, Incorporated $CYTK Stock Position Raised by Handelsbanken Fonder AB - MarketBeat
CYTK Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Assessing Cytokinetics (CYTK) Valuation After Recent Share Price Weakness And Aficamten Expectations - Yahoo Finance
A Look At Cytokinetics (CYTK) Valuation After Recent Share Price Pullback - simplywall.st
Monashee Investment Management LLC Buys Shares of 100,000 Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics (HAM:KK3A) Total Receivables : €1.54 Mil (As of Sep. 2025) - GuruFocus
Cytokinetics (HAM:KK3A) Inventories, Raw Materials & Components : €0.00 Mil (As of Sep. 2025) - GuruFocus
TD Asset Management Inc Raises Stake in Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics (HAM:KK3A) Inventories, Inventories Adjustments : €0.00 Mil (As of Sep. 2025) - GuruFocus
Cytokinetics (HAM:KK3A) YoY Rev. per Sh. Growth : 250.00% (As of Sep. 2025) - GuruFocus
Cytokinetics (HAM:KK3A) FCF Margin % : -6,037.84% (As of Sep. 2025) - GuruFocus
Cytokinetics (HAM:KK3A) Total Equity : €-444.00 Mil (As of Sep. 2025) - GuruFocus
Cytokinetics (HAM:KK3A) Research & Development : €0.00 Mil (TTM As of Sep. 2025) - GuruFocus
HC Wainwright Estimates Cytokinetics Q3 Earnings - MarketBeat
Cytokinetics (HAM:KK3A) 1-Year ROIIC % : -84.62% (As of Sep. 2025) - GuruFocus
Cytokinetics (HAM:KK3A) Investments And Advances : €246.07 Mil (As of Sep. 2025) - GuruFocus
Cytokinetics (HAM:KK3A) COGS-to-Revenue : 51.27 (As of Sep. 2025) - GuruFocus
Cytokinetics (HAM:KK3A) Land And Improvements : €0.00 Mil (As of Sep. 2025) - GuruFocus
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):